Astragaloside IV Regulates Insulin Resistance and Inflammatory Response of Adipocytes Via Modulating CTRP3 and PI3K/AKT Signaling
Overview
Affiliations
Introduction: Emerging evidence showed that adipocytes are important regulators in controlling insulin resistance in type 2 diabetes mellitus (T2DM). So far, compounds isolated from natural plants have been widely studied for their roles in alleviating T2DM-associated complications. This work evaluated the actions of astragaloside IV (AS-IV) on insulin resistance and inflammatory biomarker expression in adipocytes and explored the potential mechanisms.
Methods: Glucose consumption of the adipocytes was determined by a glucose assay kit; the mRNA expression levels of glucose transporter type 4 (GLUT-4), interleukin-6 (IL-6), TNF-α and C1q tumor necrosis factor-related protein 3 (CTRP3) were measured by quantitative real-time PCR (qRT-PCR); the protein levels were determined by western blot assay and enzyme-linked immunosorbent assay.
Results: AS-IV concentration-dependently increased glucose consumption in the insulin resistance adipocytes. Further qRT-PCR results showed that AS-IV concentration-dependently reduced adipocyte IL-6 and TNF-α expression. Moreover, GLUT-4 expression in adipocytes was also significantly upregulated by AS-IV. Furthermore, we found that AS-IV concentration-dependently increased CTRP3 expression in adipocytes. CTRP3 silence decreased glucose consumption, upregulated IL-6 and TNF-α expression and downregulated GLUT-4 mRNA expression in 200 µM AS-IV-treated adipocytes. Moreover, AS-IV treatment enhanced the activity of phosphoinositide 3-kinase (PI3K)/AKT signaling in adipocytes, which was markedly attenuated by CTRP3 silencing. Importantly, inhibition of PI3K/AKT signaling also attenuated AS-IV induced an increase in glucose consumption and GLUT-4 expression and a decrease in IL-6 and TNF-α expression of adipocytes.
Conclusions: Collectively, our data indicated that AS-IV attenuated insulin resistance and inflammation in adipocytes via targeting CTRP3/PI3K/Akt signaling.
Li X, Wang F, Chen M, Ling L, Zhao F, Peng D BMC Womens Health. 2024; 24(1):366.
PMID: 38909214 PMC: 11193179. DOI: 10.1186/s12905-024-03218-5.
Feng Y, Ren Y, Zhang X, Yang S, Jiao Q, Li Q Front Pharmacol. 2024; 15:1373711.
PMID: 38799166 PMC: 11116707. DOI: 10.3389/fphar.2024.1373711.
Gu H, Zhong L, Zhang Y, Sun J, Liu L, Liu Z Sci Rep. 2024; 14(1):10286.
PMID: 38704482 PMC: 11069553. DOI: 10.1038/s41598-024-61011-8.
Shi L, Tan Y, Zheng W, Cao G, Zhou H, Li P Cell Death Discov. 2024; 10(1):53.
PMID: 38278820 PMC: 10817931. DOI: 10.1038/s41420-024-01813-x.
Could Cyclosiversioside F Serve as a Dietary Supplement to Prevent Obesity and Relevant Disorders?.
Qin S, Chen J, Zhong K, Li D, Peng C Int J Mol Sci. 2023; 24(18).
PMID: 37762063 PMC: 10531328. DOI: 10.3390/ijms241813762.